Incretin Polyagonists Emerge as Potent Non-Surgical Alternative for Obesity Management

Globally, obesity is a significant public health crisis, leading to numerous comorbidities like type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. While bariatric surgery offers substantial and sustained weight loss, it is an invasive procedure with potential risks and limited accessibility. This review addresses the urgent need for highly effective, less invasive pharmacological interventions that can rival the efficacy of surgical options for severe obesity.

The review highlighted that incretin polyagonists demonstrate remarkable efficacy in promoting significant and sustained weight loss. For instance, clinical trials showed tirzepatide at its highest dose (15 mg weekly) resulted in an average total body weight reduction of 20.9% (approximately 24 kg) over 72 weeks in individuals with obesity, compared to 3.1% with placebo (p<0.001). Even more impressively, retatrutide demonstrated up to 24.2% mean weight reduction in Phase 2 trials. These pharmacological interventions also led to substantial improvements in metabolic parameters, including reductions in HbA1c by 2.0% and systolic blood pressure by 7.4 mmHg. > The most significant finding is that these advanced incretin polyagonists achieve weight loss outcomes that are quantitatively comparable to, and in some cases exceed, those observed with certain types of bariatric surgery, such as sleeve gastrectomy, which typically results in 25-30% excess weight loss.